Dianthus Therapeutics (NASDAQ:DNTH) Sees Large Volume Increase on Analyst Upgrade

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) saw an uptick in trading volume on Wednesday after Guggenheim raised their price target on the stock from $92.00 to $100.00. Guggenheim currently has a buy rating on the stock. 804,682 shares changed hands during trading, an increase of 117% from the previous session’s volume of 371,567 shares.The stock last traded at $36.09 and had previously closed at $35.57.

A number of other analysts have also commented on DNTH. Wedbush boosted their price objective on shares of Dianthus Therapeutics from $34.00 to $42.00 and gave the stock an “outperform” rating in a research report on Thursday, August 21st. William Blair initiated coverage on shares of Dianthus Therapeutics in a report on Wednesday, July 2nd. They set an “outperform” rating on the stock. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Dianthus Therapeutics in a report on Monday. Finally, Robert W. Baird boosted their target price on shares of Dianthus Therapeutics from $50.00 to $67.00 and gave the stock an “outperform” rating in a report on Tuesday. Eight analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $60.67.

Insider Activity at Dianthus Therapeutics

In other news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $35.00, for a total value of $700,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.15% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Institutional investors have recently modified their holdings of the business. Raymond James Financial Inc. bought a new stake in shares of Dianthus Therapeutics in the second quarter valued at about $27,000. US Bancorp DE lifted its position in Dianthus Therapeutics by 2,013.3% during the first quarter. US Bancorp DE now owns 1,585 shares of the company’s stock worth $29,000 after purchasing an additional 1,510 shares during the period. BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics during the fourth quarter worth about $59,000. GAMMA Investing LLC lifted its position in Dianthus Therapeutics by 3,030.6% during the first quarter. GAMMA Investing LLC now owns 3,882 shares of the company’s stock worth $70,000 after purchasing an additional 3,758 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after purchasing an additional 3,317 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Price Performance

The company’s 50-day moving average is $22.65 and its two-hundred day moving average is $20.43. The firm has a market cap of $1.22 billion, a P/E ratio of -11.65 and a beta of 1.46.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Dianthus Therapeutics had a negative return on equity of 34.72% and a negative net margin of 2,364.56%.The firm had revenue of $0.19 million for the quarter, compared to the consensus estimate of $0.87 million. On average, analysts expect that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.